[Featured Stock] MedPacto, Nomura Securities Sets Target Price at 140,000 KRW... "Corporate Value Could Reach 8 Trillion KRW"
[Asia Economy Reporter Hyunseok Yoo] MedPacto is showing strong performance. It appears that the news of Nomura Securities setting a target price of 140,000 won has had an impact.
As of 2:01 PM on the 24th, MedPacto was trading at 97,000 won, up 6.83% (6,200 won) compared to the previous trading day.
Cara Song, a researcher at Nomura Securities, analyzed on the 23rd (local time) that MedPacto has the potential to discover new drugs in 2021. She explained that if all six indications succeed in clinical trials, the corporate value could reach approximately 7.9 trillion won.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
However, considering that most of the major pipelines are in Phase 2 clinical trials, she set the target price at 140,000 won. She emphasized that the valuation could increase each time successful results are achieved in the clinical stages.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
